Literature DB >> 8193062

Specificity of the Calgary Depression Scale for schizophrenics.

D Addington1, J Addington, E Maticka-Tyndale.   

Abstract

This study sought to determine the specificity of the Calgary Depression Scale (CDS), a depression rating scale for schizophrenics. The specificity is the degree to which the scale assesses depression rather than negative or extrapyramidal symptoms. Subjects were 100 outpatients (OP) and 50 inpatients (IP) meeting DSM-III-R criteria for schizophrenia. Negative symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS); extrapyramidal symptoms were assessed with the Simpson Angus Scale (SA) and depression with the CDS. Results were that the CDS showed no correlation with SA, but weak (0.33) statistically significant correlations with the PANSS negative symptom score in inpatients but not outpatients. Confirmatory factor analysis using Lisrel 6.0 showed that the model hypothesizing specificity of depression, negative symptoms and extrapyramidal symptoms, was significant, with a goodness of fit index of 0.89 and a root mean square residual of 0.07. It is concluded that the CDS achieves a useful degree of separation between measures of depression, negative and extrapyramidal symptoms in subjects with schizophrenia, when combined with the other measures used in this study.

Entities:  

Mesh:

Year:  1994        PMID: 8193062     DOI: 10.1016/0920-9964(94)90017-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  53 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

Review 2.  rTMS strategies for the study and treatment of schizophrenia: a review.

Authors:  Arielle D Stanford; Zafar Sharif; Cheryl Corcoran; Nina Urban; Dolores Malaspina; Sarah H Lisanby
Journal:  Int J Neuropsychopharmacol       Date:  2008-02-01       Impact factor: 5.176

3.  Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.

Authors:  Leandro da Costa Lane Valiengo; Stephan Goerigk; Pedro Caldana Gordon; Frank Padberg; Mauricio Henriques Serpa; Stephanie Koebe; Leonardo Afonso Dos Santos; Roger Alberto Marcos Lovera; Juliana Barbosa de Carvalho; Martinus van de Bilt; Acioly L T Lacerda; Helio Elkis; Wagner Farid Gattaz; Andre R Brunoni
Journal:  JAMA Psychiatry       Date:  2020-02-01       Impact factor: 21.596

4.  Factor Analysis of Negative Symptom Items in the Structured Interview for Prodromal Syndromes.

Authors:  Matilda Azis; Gregory P Strauss; Elaine Walker; William Revelle; Richard Zinbarg; Vijay Mittal
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

5.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

6.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Authors:  Jean Addington; Hely Shah; Lu Liu; Donald Addington
Journal:  Schizophr Res       Date:  2014-01-16       Impact factor: 4.939

7.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

8.  Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.

Authors:  Rosa Ayesa-Arriola; Jose Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; Roberto Roiz-Santiáñez; Obdulia Martínez-García; Jose Sánchez-Moreno; Rafael Tabarés-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

9.  A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.

Authors:  Judith Rietdijk; Sara Dragt; Rianne Klaassen; Helga Ising; Dorien Nieman; Lex Wunderink; Philippe Delespaul; Pim Cuijpers; Don Linszen; Mark van der Gaag
Journal:  Trials       Date:  2010-03-22       Impact factor: 2.279

10.  Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.

Authors:  Adel Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.